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Abstract
Background: Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and
response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard
regimen to improve the outcome of these patients. The purpose of this study is to evaluate the prognostic impact
of the American Joint Committee on Cancer (AJCC) response criteria and this tool’s usefulness in four different
breast cancer subtypes.
Methods: We conducted a retrospective cohort study of clinical stage II/III breast cancer patients who received
NAC of more than 6 cycles. Response after NAC and the clinicopathological factors were reviewed. AJCC response
criteria for NAC were adopted from the AJCC Manual, 7th edition: complete response (CR), partial response (PR),
and no response (NR).
Results: A total of 183 patients were enrolled; 22 (12.0 %), 123 (67.2 %), and 38 (20.8 %) patients showed CR, PR,
and NR, respectively. The AJCC response was significantly associated with relapse-free survival (RFS) (P < 0.001),
whereas pathologic CR (pCR), the current gold standard for response evaluation for NAC, was not (P = 0.140). AJCC
response was a significant prognostic factor for RFS in all four breast cancer subtypes, namely luminal A (P = 0.006),
luminal B (P = 0.001), HER-2 enriched (P = 0.039), and triple-negative breast cancer (P = 0.035).
Conclusions: The AJCC response criteria represent a simple and easily reproducible tool for response evaluation of
NAC patients and a useful clinical prognostic marker for RFS. These criteria also have a prognostic impact in all four
breast cancer subtypes, including luminal A in which pCR has a limited role.
Keywords: Stage II or III, Breast neoplasm, Neoadjuvant chemotherapy, American Joint Committee on Cancer
(AJCC) response, Relapse-free survival, Breast cancer subtype
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Background
Breast cancer is the most common cancer in women
worldwide, and 1.68 million cases are newly diagnosed
annually [1]. It is the second most common cancer in fe-
males in South Korea, where 15,942 women were newly
diagnosed in 2011 [2]. About 44 % of the newly diag-
nosed breast cancer patients are initially stage II or III,
and neoadjuvant chemotherapy (NAC) or primary sys-
temic therapy has become the standard treatment for
this population [3, 4]. Response to NAC is known to be
useful in prognostic and predictive aspects. Pathologic
complete response (pCR) is the most useful surrogate
marker for overall survival in the NAC setting [5–7].
However, despite its clinical usefulness, pCR alone has
limitations in evaluating residual disease after NAC. Re-
cent pooled analysis of neoadjuvant clinical trials re-
vealed that pCR is not a surrogate end-point marker for
survival in the overall population because response to
NAC is heterogeneous among breast cancer subgroups
[8]. Several methods have been devised to evaluate the
response to NAC, one of which is the American Joint
Committee on Cancer (AJCC) response criteria for NAC
[9]. Keam et al. [10] validated AJCC response criteria for
NAC in 398 patients who received 3 cycles of doxorubi-
cin plus docetaxel, and found these criteria to be useful
in evaluating the response to NAC as well as predicting
survival after short-course NAC.
Since the middle of the last decade the importance of
pCR achievement has been emphasized, and to obtain
higher rates of pCR extended cycles of neoadjuvant
chemotherapy have been introduced [11, 12]. Six to
eight cycles of NAC has recently become the standard
treatment in clinical practice. In this study, we evaluated
the clinical impact of AJCC response criteria in patients
undergoing six or more cycles of NAC. In addition, we
evaluated the clinical usefulness and prognostic value of
the AJCC criteria in four different breast cancer sub-
groups [13].
Methods
Study population and treatment
We conducted a retrospective cohort study of the pa-
tients who received NAC in Seoul National University
Hospital. Between January 2009 and December 2010, all
stage II/III breast cancer patients receiving NAC were
screened.
Detailed eligibility criteria were as follows: (1) patho-
logically confirmed breast cancer by core needle biopsy;
(2) clinical stage II or III; (3) presence of objective
measurable lesion by Response Evaluation Criteria In
Solid Tumors (RECIST) version 1.1 [14]; (4) Eastern
Cooperative Oncology Group performance status 0–2;
(5) previously untreated; (6) cycles of neoadjuvant
chemotherapy of 6 or more. Initial evaluation included
physical examination, mammography, breast ultrasonog-
raphy, chest computed tomography (CT), bone scan,
and breast magnetic resonance imaging (MRI). Initial
tumor size was measured by MRI. Initial nodal staging
was determined by physical examination and CT. After
completing six or more cycles of neoadjuvant chemo-
therapy before definitive surgery, the patients were re-
examined for response evaluation. Thereafter, the pa-
tients received curative surgery followed by adjuvant
chemotherapy according to the physician’s decision, con-
sidering response to NAC and final pathologic stage
[15]. Patients received additional adjuvant radiation ther-
apy [16], trastuzumab [17, 18], and hormonal therapy
[19], if indicated.
The study protocol was reviewed and approved by
the Institutional Review Board at the Seoul National
University Hospital (H-0510-506-159). Recommendations
of the Declaration of Helsinki for biomedical research
involving human subjects were also followed.
Response evaluation
For evaluation of radiologic response, we obtained ultra-
sonography and MRI for primary breast cancer and
chest CT for lymph node evaluation before and after
NAC. The radiologic response was evaluated by RECIST
criteria version 1.1 [14]. The initial clinical and post-
NAC pathologic staging was based on the AJCC Cancer
Staging Manual, 7th edition. The details of AJCC re-
sponse criteria for NAC were as follows [9].
(1)Complete response (CR) is defined as the absence of
invasive carcinoma in the breast and lymph nodes.
Residual in situ cancer, in the absence of invasive
disease, constitutes a CR. Patients with isolated
tumor foci in lymph nodes are not classified as
having a CR.
(2)Partial response (PR) is defined as a decrease in
either or both T or N stage compared to the
pretreatment T or N, and no increase in either T
or N. After chemotherapy, one should use the
method that most clearly defined tumor dimensions
at the baseline for this comparison, although pre-
chemotherapy pT cannot be measured.
(3)No response (NR) is defined as no apparent change
in either the T or N categories compared to the
clinical pretreatment assignments, or increase in
either the T or N categories at the time of pathologic
evaluation.
Pathologic complete response (pCR) is defined as
complete disappearance of invasive carcinoma, in both
the breast and the axillary lymph nodes, after NAC.
Residual ductal carcinoma in situ (DCIS) was included
in the pCR category.
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Clinicopathological examination
The clinical characteristics (age at diagnosis, date of
diagnosis, date, cycles and regimen of neoadjuvant
chemotherapy, date of surgery, adjuvant therapy, date of
last visit, date of relapse) and the laboratory test results
(follicle-stimulating hormone, luteinizing hormone, and
estradiol levels at diagnosis for determination of meno-
pausal status [20]) were obtained by retrospective review
of electronic medical records. We performed immuno-
histochemistry (IHC) using tissues obtained at diagnosis.
Estrogen receptor (ER), progesterone receptor (PR), hu-
man epidermal growth factor receptor 2 (HER2), p53,
Bcl-2, epidermal growth factor receptor (EGFR), and Ki-
67 expression were evaluated. IHC was performed as
previously described in our center’s study series [21–24].
In the case of HER2 IHC 2+, fluorescence in situ
hybridization (FISH) was performed to determine HER2
positivity. Positivity thresholds for classification were
ER ≥ 1 %; PR ≥ 1 % [25]; HER2 = IHC 3+ (>10 % invasive
tumor cells with intense and circumferential membrane
staining) and/or FISH positive (HER2/CEP17 ratio ≥ 2.2)
[26, 27]; and p53 ≥ 25 % [22, 28]. The Ki-67 threshold of
high (≥14 %) was based on work by Cheang et al., in
which 14 % best discriminated between luminal-A and
luminal-B tumors [29].
Breast cancer subtypes
Breast cancer is further classified into several groups ac-
cording to their molecular alteration, cellular compos-
ition, and clinical outcome. Tumor classification is
useful in determining and predicting response to treat-
ment as well as providing prognostic information. In this
study, we classified breast cancer patients into four sub-
groups, namely luminal A (LA), luminal B (LB), HER2
enriched (HER2), and triple-negative breast cancer
(TNBC), these definitions being mainly adopted from
the 2011 St Gallen Consensus Panel [30]. Definitions of
each subgroup are as follows.
(1)LA (highly endocrine responsive): ER positive, PR
positive, HER2 negative, and Ki-67 low. The few
ER-negative/PR-positive cases were considered ER-
positive/PR-positive.
(2)LB (moderately endocrine responsive): ER positive
and PR negative independent of other parameters, or
ER positive, PR positive and at least one of grade 3,
HER2 positive, and/or Ki-67 high.
(3)HER2: ER negative, PR negative, and HER2 positive.
(4)TNBC: ER negative, PR negative, and HER2 negative
regardless of the expression of EGFR and basal
cytokeratins.
Although there is some controversy surrounding
endocrine therapy for patients with low ER-expressing
tumors (1–10 %, weakly positive) regarding the benefit
of tamoxifen and other endocrine therapies on sur-
vival and their relatively low toxicities, the American
Society of Clinical Oncology (ASCO) and the College
of American Pathologists (CAP) Panel recommended
that ER and PR assays be considered positive if there
are at least 1 % positive tumor nuclei in the sample
[25, 31, 32]. The recent National Comprehensive Cancer
Network guideline for breast cancer also adopted the
ASCO/CAP recommendation. We adopted the ASCO/
CAP guideline to determine the hormone receptor-
positive tumors.
Statistical analysis
Relapse-free survival (RFS) was determined as the inter-
val between the initiation of neoadjuvant chemotherapy
and the date when disease relapse or progression was
first documented, or the date of death from any cause.
Local, regional, and distant relapse were all included in
disease relapse, and contralateral breast cancer was not
regarded as relapse. The Kaplan–Meier product limit
method and the Cox proportional hazards regression
model were used for survival analyses. Log-rank tests
were used to compare RFS between different subgroups.
Differences between breast cancer subtypes with regard
to clinicopathologic characteristics were examined using
1-way analysis of variance (ANOVA) for the continuous
variables (age, pre- and post-NAC tumor size), and χ2
tests for the remaining variables. All statistical tests were
two-sided, with the level of significance established at
P < 0.05. All statistical analyses were carried out using
SPSS version 21.0 (SPSS, Chicago, IL, USA).
Results
Patients and treatment
During the study period, 249 stage II/III breast cancer
patients received NAC in Seoul National University
Hospital. Sixty-six patients were excluded because they
received less than six cycles of NAC, and finally 183 pa-
tients of median age 46 (range 25–71) years were en-
rolled and evaluated. The median follow-up duration
was 38.0 (range 9–53) months. At the data cut-off point
in June 2013, 41 patients (22.4 %) had developed recur-
rent disease. The median RFS was not reached at the
time. One hundred and fifty-three patients (83.6 %) were
stage III. One hundred and nine (59.6 %) were premeno-
pausal, and 106 (57.9 %) had hormone receptor-positive
tumors. The majority of the patients received both
anthracycline- and taxane-containing NAC. A total of
128 (69.9 %) received a concurrent anthracycline and
taxane regimen, and 47 (25.7 %) received sequential
anthracycline and taxane. Ten patients (32.3 % of
HER2-positive patients) received a HER2-targeted agent
(trastuzumab or trastuzumab emtansine)-containing NAC
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regimen. The baseline characteristics of the 183 patients
are summarized in Table 1.
Response to the neoadjuvant chemotherapy and
relapse-free survival
The results of the response evaluation after NAC ac-
cording to the AJCC response criteria are shown in
Table 2. Among 183 patients there were 22 with CR
(12.0 %), 123 with PR (67.2 %), and 38 with NR (20.8 %).
The 3-year RFS rates were 90.9 % in CR, 79.9 % in PR,
and 48.5 % in NR patients (Fig. 1, log-rank P < 0.001).
AJCC response was significantly associated with RFS
(the hazard ratio (HR) for relapse of CR/PR group vs.
NR group was 0.269, with 95 % confidence interval (CI)
of 0.141–0.513, P < 0.001). Figure 2 shows the hazard
rate of relapse at the specific time from diagnosis
(months) according to the three AJCC response groups.
In the NR group, about 27 % of patients relapsed within
1 year and 52 % relapsed within the first 3 years from
diagnosis, even during the adjuvant chemotherapy,
radiotherapy, or hormone therapy. The AJCC response
CR and PR groups showed similar prognosis and no
statistical difference of RFS probability (HR of PR group
2.067, 95 % CI 0.485–8.803, P = 0.326), but the PR and
NR groups showed a significant difference in RFS
probability (HR of NR group 3.665, 95 % CI 1.879–
7.146, P < 0.001). After adjusting for potential prognostic
factors, the AJCC response was independently associated
with RFS (P = 0.004, Table 3), as well as the traditional
prognostic factors such as pathologic stage and hormone
receptor positivity. The pCR was not a significant pre-
dictor of RFS (Fig. 3, log-rank P = 0.110), despite the
Kaplan–Meier curve showing a tendency for survival dif-
ference between the two groups.
Breast cancer subgroup analysis
We divided the patients into four subgroups (LA, LB,
HER2, and TNBC) as previously described, comprising
44 (24.1 %), 62 (33.9 %), 31 (16.9 %), and 46 (25.1 %) pa-
tients, respectively. The rate of pCR was higher in TNBC
(19.6 %), HER2 (16.1 %), and LB (12.9 %) groups than in
the LA (0 %) group. The rate of AJCC response of CR
plus PR was also higher in the TNBC (82.6 %), HER2
(87.1 %), and LB (79.0 %) groups than in the LA (70.5 %)
group. The response to the NAC according to the AJCC
criteria was a significant prognostic factor for RFS in all
four subgroups: LA (P = 0.006), LB (P = 0.001), HER2
(P = 0.039), and TNBC (P = 0.035) (Fig. 4, log-rank
test). In all subgroups, CR and PR patients showed a
similar hazard rate of relapse: HR of PR patients was
not assessable (no CR in LA group), 26.953 (P = 0.618),
2.690 (P = 0.345), and 1.613 (P = 0.663) in LA, LB, HER2,
Table 1 Baseline characteristics
Variables Number of patients (N = 183)
No %
Age, median (range) 46 (25–71)
Histology
Invasive ductal carcinoma 167 91.3
Premenopausal/Postmenopausal 109/74 59.6/40.4
Regimen of Neoadjuvant Chemotherapy
Concurrent anthracycline + taxane 128 69.9
Sequential anthracycline + taxane 47 25.7
HER-2 directed agent containing
regimen
10 5.5
Doxorubicin plus cyclophosphamide 1 0.5
Type of Surgery








Hormone receptor and HER2 expression
status
Hormone receptor (+) 106 57.9










Radiation therapy 158 86.3
Chemotherapy 62 33.9
Trastuzumab 55 94.8 % of patients with
HER2 positive tumor
Hormonal therapy 103 97.1 % of patients with
HR positive tumor
HER2 human epidermal growth factor receptor 2, TNBC triple negative
breast cancer
Table 2 AJCC response after neoadjuvant chemotherapy





CR complete response, PR partial response, NR no response
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and TNBC groups, respectively. Interestingly, NR patients
showed a significantly higher risk of relapse than PR pa-
tients in all the four breast cancer subgroups: HR of NR
patients was 12.898 (95 % CI 1.285–129.437, P = 0.030),
4.224 (95 % CI 1.088–16.394, P = 0.037), 5.044 (95 % CI
1.555–16.366, P = 0.007), and 4.206 (95 % CI 1.121–
15.786, P = 0.033) in the LA, LB, HER2, and TNBC
groups, respectively. On the contrary, pCR was not signifi-
cantly associated with RFS in any subgroups (Table 4).
Pathologic stage was significantly associated with RFS in
HER2 and TNBC patients, but not in the LA and LB
groups. Table 4 shows the prognostic factors for RFS in
each breast cancer subgroup by Cox regression.
Discussion
Response to the neoadjuvant chemotherapy in stage II
or stage III breast cancer has a prognostic impact on
RFS and overall survival [33–35]. pCR is the current
standard criterion for evaluation of the response after
NAC [5–7]. Addition of preoperative taxanes to doxorubi-
cin and cyclophosphamide (AC) increased the proportion
of patients with pCR compared with preoperative AC
alone (26 % vs. 13 %, respectively; P < 0.001) [11, 36].
Following publication of the results of NSABP B-27
together with B-18 and several other studies, ex-
tended NAC to obtain a higher pCR rate became the
standard treatment in clinical practice [11, 12, 36, 37].
Despite its clinical usefulness, pCR has some limitations
as a prognostic and predictive marker, and several groups
proposed new methods for grouping post-NAC patients
to evaluate the response to NAC [35, 38, 39], one of which
is the AJCC response criteria for NAC. A previous study
by Keam et al. [10] showed that the AJCC response cri-
teria for NAC correlate well with radiologic response cri-
teria and have a prognostic value for both RFS and overall
survival in patients with three cycles of concurrent doxo-
rubicin plus docetaxel neoadjuvant chemotherapy. CR,
PR, and NR rates were 9.8, 59.3, and 30.7 %, 5-year RFS
89.6, 74.1, and 62.6 % (P = 0.002), and 5-year overall sur-
vival 97.4, 88.6, and 78.3 % (P = 0.012), respectively [10].
In the current study, we demonstrated that the AJCC re-
sponse criteria represent a useful prognostic factor for
RFS in patients undergoing 6 or more cycles of NAC. The
rates of CR and PR are significantly higher (12 and 67.2 %,
respectively) than those from 3 cycles of NAC in the
previous study [10]. Because the follow-up duration is
short, the prognostic impact of AJCC response with ex-
tended NAC on the overall survival has not yet been
obtained.
Previous studies reported different rates of pCR after
NAC between breast cancer subgroups, and suggested
the clinical usefulness of pCR as a surrogate marker of
survival is different in each breast cancer subtype [13].
According to von Minckwitz et al., pCR is a suitable sur-
rogate end point for patients with LB/HER2-negative,
HER2-positive (non-luminal), and triple-negative disease
but not for those with LB/HER2-positive or LA tumors
[13]. LA is a slowly proliferating tumor type, whose re-
sponse to NAC is not as good as that in highly prolifer-
ating tumor types. Given these heterogeneous responses
to NAC, a recent meta-analysis revealed that pCR alone
is not sufficient as a surrogate end point for event-free
survival and overall survival in the general breast cancer
population [8]. In fact, no patients achieved pCR in the
LA group in our current study. Furthermore, in contrast
to previous studies, pCR was not associated with RFS in
any of our subgroups. This might result from a short
follow-up period and a lack of sufficient events (relapse)
for obtaining statistical power. By contrast, our analyses
of the four breast cancer subtypes demonstrated that
AJCC response after NAC was a significant prognostic
marker for RFS in all four breast cancer subgroups, even
in LA patients.
Fig. 1 Relapse-free survival probability according to the American
Joint Committee on Cancer (AJCC) response, complete response,
partial response, and no-response groups
Fig. 2 Hazard rates of relapse of breast cancer patients after
diagnosis according to the AJCC response criteria
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There was no significant difference in RFS between
pCR and non-pCR groups (P = 0.110, log-rank test). The
AJCC response in CR and PR patients showed a similar
prognosis, but PR and NR groups showed a significant
difference in RFS probability. We also compared the RFS
of CR + PR groups with that of the NR group using
AJCC response criteria. The RFS of CR + PR patients
was significantly longer than that in the NR group
(median RFS not reached vs. 29 months, P < 0.001, log-
rank test). The RFS probability difference between the
CR and PR groups was not significantly different, al-
though the HR of PR patients was higher, at 2.067 (95 %
CI 0.485–8.803, P = 0.326). This might result from the
small sample size and, thus, insufficient events (sample
size 145 and 24 events at the data cut-off ). The AJCC
response criteria may thus represent a simple and easily
applicable tool to evaluate residual disease and a new
surrogate end point in neoadjuvant trials. Further
follow-up is needed to confirm the prognostic impact of
the AJCC response criteria and pCR in each breast can-
cer subgroup.
We further analyzed the LA patients. In our hospital’s
NAC cohort, we were able to obtain the clinicopatho-
logic and survival data of all the LA patients, regardless
of the number of NAC cycles (<6 or ≥6 cycles). For the
LA patients, pCR was achieved in neither group. The
AJCC response rate (CR + PR portion) was higher in the
extended-NAC group than in the short-course NAC
group (70.5 % vs. 56.3 %), although statistically not sig-
nificant (P = 0.302). This trend is consistent with the
previous report by Moon et al. [40], which showed that
continuous tumor shrinkage occurred in their ER-
positive tumor group during extended NAC, while
tumor shrinkage mainly occurred in the early period of
NAC in the ER-negative group. By Cox regression of
prognostic factors on RFS in the LA subgroup, premen-
opausal patients showed a significantly lower risk of re-
lapse than the postmenopausal patients (HR 0.092, 95 %
CI 0.009–0.906, P = 0.041; Table 4). This benefit might
result from the additional secondary ovarian function
suppression effect of chemotherapeutic agents in pre-
menopausal patients. All things considered, in younger
LA patients in premenopausal status an extended-NAC
strategy might be more beneficial.
From the hazard rate of RFS of the patients according
to AJCC responses (Fig. 2), we discerned several clinical
implications. In the NR group 27, 41, and 52 % of
the patients relapsed during first 1, 2, and 3 years
after diagnosis, respectively. For these patients, thor-
ough physical examination and work-up for locoregio-
nal and/or distant metastases should be performed
even during adjuvant therapies. From these data, we
may suggest the necessity of further adjuvant chemo-
therapy even after the use of both an anthracycline-
and taxane-containing NAC regimen and the selection
Table 3 Univariate and multivariate analyses for relapse free survival
Variables Univariate analysis Multivariate analysis
HR 95 % CI P HR 95 % CI P
Age (≤median) 0.685 0.364–1.287 0.240 -
Menopausal status (Premenopausal) 0.846 0.449–1.594 0.605 -
pCR 0.342 0.082–1.420 0.140 -
AJCC response (CR plus PR) 0.309 0.172–0.556 0.000 0.374 0.192–0.728 0.004
Surgery (BCS) 0.428 0.228–0.803 0.008 0.475 0.252–0.894 0.021
Pathologic Stage (yp0,I) 0.235 0.092–0.600 0.002 0.267 0.094–0.756 0.013
Hormone receptor positive 0.447 0.236–0.846 0.013 0.402 0.198–0.818 0.012
HER2 positive 1.059 0.761–1.474 0.734 -
TNBC 1.038 0.056–2.131 0.919 -
Subtype (Luminal A) 0.379 0.145–0.985 0.047 0.314 0.103–0.962 0.043
pCR pathologic complete response, CR complete response, PR partial response, BCS breast conserving surgery, HER2 human epidermal growth factor receptor 2,
TNBC triple negative breast cancer, HR hazard ratio, 95 % CI 95 % confidence interval, P p-value
Fig. 3 Relapse-free survival probability according to the pathologic
complete response
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of high-risk patients who require adjuvant chemotherapy.
Ongoing adjuvant clinical trials (JBCRG04 (CREATE-X),
NCT01864746 (PENELOPE-B)) are targeting high-risk
patients with residual diseases after neoadjuvant chemo-
therapy. The recent results of the CREATE-X trial
revealed that treatment with adjuvant capecitabine in-
creased disease-free survival for patients with HER2-
negative breast cancer who had residual disease after
neoadjuvant chemotherapy [41]. The data also showed
a tendency toward improving overall survival, albeit
a b
c d
Fig. 4 Relapse-free survival probability according to the AJCC response in each breast cancer subgroup: a luminal A type, b luminal B type,
c HER2-enriched type, and d triple-negative breast cancer type
Table 4 Prognostic factors according to subgroup analysis
Variables Luminal A Luminal B HER2 TNBC
HR 95 % CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P
Age
≤median 0.477 0.078–2.907 0.422 0.646 0.207–2.019 0.453 0.616 0.188–2.016 0.423 0.597 0.168–2.115 0.424
>median 1 1 1 1
Menopausal status
Premenopausal 0.092 0.009–0.906 0.041 0.875 0.282–2.727 0.818 0.482 0.132–1.754 0.268 0.741 0.214–2.558 0.635
Postmenopausal 1 1 1 1
pCR - 0.039 0.000–46.767 0.370 0.360 0.047–2.773 0.327 0.420 0.053–3.323 0.411
vs non-pCR 1 1 1
AJCC response
CR plus PR 0.078 0.008–0.778 0.030 0.157 0.050–0.499 0.002 0.221 0.058–0.838 0.026 0.219 0.061–0.783 0.020
NR 1 1 1 1
Pathologic Stage
yp0,I 0.517 0.247–1.081 0.080 0.160 0.021–1.238 0.079 0.162 0.036–0.732 0.018 0.182 0.038–0.861 0.032
ypII, III, IV 1 1 1 1
Surgery
BCS 0.414 0.069–2.493 0.336 0.329 0.101–1.071 0.065 0.296 0.081–1.081 0.065 0.930 0.240–3.660 0.917
Mastectomy 1 1 1 1
pCR pathologic complete response, CR complete response, PR partial response, NR no response, BCS breast conserving surgery, HER2 human epidermal growth
factor receptor 2, TNBC triple negative breast cancer, HR hazard ratio, 95 % CI 95 % confidence interval, P p-value
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statistically insignificant, which might derive from the
short follow-up period.
Our study has some limitations. First, because of the
retrospective design of the study, the probability existed
of selecting patients with a good response to NAC
(whose cancer did not progress during NAC) while ex-
cluding patients with early progression or non-response.
The investigation of those who received a short course
of NAC (<6 cycles, total n = 66) provided some clues.
They encompassed both groups who were initially
scheduled to receive a short course of chemotherapy
and who progressed during NAC. Although it was diffi-
cult to distinguish the two groups by retrospective med-
ical record review, there was only one patient with
definite clinical disease progression during NAC who re-
ceived mastectomy after three cycles of NAC. According
to the radiologic response criteria, there was no differ-
ence in the portion of patients with progressive disease
(4.5 % vs. 4.4 %, <6 cycles vs. ≥6 cycles of NAC). There-
fore, the selection bias is expected to be minimal in this
study. Second, the follow-up duration in this study is
short, so the prognostic impact of the AJCC response
criteria on overall survival for a long course of NAC
could not be demonstrated. Third, the sample sizes of
the each breast cancer subgroup are rather small, so the
prognostic impact of the AJCC response criteria in each
breast cancer subtype should be investigated in a larger
population in subsequent studies.
Despite these limitations, this is the first report to
demonstrate the clinical usefulness of AJCC response
criteria in patients undergoing six or more cycles of
NAC with neoadjuvant chemotherapy regimens used in
clinical practice. Furthermore, our analyses demon-
strated that the AJCC response criteria represented a
significant prognostic marker for RFS in all four breast
cancer subgroups, including the LA subgroup in which
pCR has a limited role. The AJCC response criteria serve
as a simple and easily reproducible tool for response
evaluation in breast cancer patients in the NAC setting
in comparison with the classically used Residual Cancer
Burden measurement method or Miller-Payne grading
system [35, 38]. The AJCC response criteria could
help overcome the limitations of pCR, as they may be
valid in all breast cancer subgroups and be helpful in
selecting those high-risk patients who need further
adjuvant treatment. In addition, we performed a pre-
and post-NAC paired imaging study (breast MRI or
chest CT with breast ultrasonography) for accurate
clinical staging, examination of radiologic response,
and evaluation of AJCC response. Further follow-up
is needed to establish the potential prognostic role of
the AJCC response criteria and other clinicopatho-
logic markers of overall survival in the NAC setting
of six to eight cycles.
Conclusions
The AJCC response criteria represent a simple and easily
reproducible clinical tool for predicting RFS in patients
with stage II/III breast cancer undergoing six or more
cycles of neoadjuvant chemotherapy. It has a prog-
nostic impact in all four breast cancer subtypes, in-
cluding the LA group in which pCR has a limited
role. The AJCC response to NAC could also be a use-
ful tool for selecting high-risk patients who need fur-
ther adjuvant chemotherapy and more thorough
examination for relapse, together with classical prog-
nostic markers such as pathologic stage and breast
cancer subtypes.
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